memo - Magazine of European Medical Oncology OnlineFirst articles

Open Access 16.05.2024 | short review

Liquid profiling for patients with advanced cancer is ready for clinical integration

Molecular profiling of circulating tumor DNA (ctDNA) to guide treatment decisions has found its way into routine management of patients with advanced cancer. This represents a pivotal advancement in precision oncology, offering a non-invasive and …

verfasst von:: Samantha O. Hasenleithner, Prof. Mag. Dr. Ellen Heitzer

PDF-Version jetzt herunterladen Zum Volltext

Open Access 30.04.2024 | short review

The molecular tumor board—a key element of precision oncology

Tumor profiling techniques have become an essential tool in cancer diagnostics creating an opportunity for individualized cancer care. Interpretation of results of molecular analyses and their integration into clinical practice, however, can be …

verfasst von:: Dr. Laura Boos, MHBA, Prof. Dr. Dr. Andreas Wicki

PDF-Version jetzt herunterladen Zum Volltext

Open Access 29.04.2024 | case report

NEC versus NET G3—is there a grey zone? Case report of pancreatic NET G3 with rapid disease progression

In 2017, the World Health Organization (WHO) Classification of Tumors of Endocrine Organs introduced a new category of neuroendocrine tumors (NET), the so-called NET G3 [ 1 ]. These tumors were separated from the former group of high-grade …

verfasst von:: Philipp Melhorn, Markus Raderer, Peter Mazal, Nicolas Kozakowski, Barbara Kiesewetter

PDF-Version jetzt herunterladen Zum Volltext

Open Access 23.04.2024 | short review

Liquid biopsy in breast cancer

Currently, the main clinical application of liquid biopsy (LB) in breast cancer (BC) is the circulating tumor DNA (ctDNA)-based detection of treatment targets in metastatic or advanced disease. In this short review we focus on clinically relevant …

verfasst von:: Eva Valentina Klocker, Christoph Suppan

PDF-Version jetzt herunterladen Zum Volltext

Open Access 22.04.2024 | case report

Alternating chemotherapy with VDC-IE as effective first-line treatment in a patient with SMARCA4-deficient undifferentiated tumor

SMARCA4-deficient undifferentiated tumor (SMARCA4-UTs) is an extremely rare and aggressive entity where no consensus on systemic treatment exists to date. We report the case of a 43-year-old woman with thoracic SMARCA4-UT who presented with rapid …

verfasst von:: Petar Popov, Oskar Steinbrecher, Anke Scharrer, Markus Raderer, Thomas Brodowicz, Matthias Preusser, Wolfgang Lamm, MD

PDF-Version jetzt herunterladen Zum Volltext

18.04.2024 | short review

American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia

In recent years, there has been massive advances in the treatment of chronic lymphocytic leukemia (CLL) from chemoimmunotherapy to the combination of targeted agents (BTK inhibitors, BCL2 inhibitors, anti-CD20 antibody), which should be …

verfasst von:: Dr. Thomas Nösslinger

Open Access 26.03.2024 | review

15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Cancer stem cells, also known as leukemic stem cells (LSC) in the context of leukemias, are an emerging topic in translational oncology and hematology. The Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO) was established in 2008 …

verfasst von:: Peter Valent, M.D., Emir Hadzijusufovic, D.V.M., Irina Sadovnik, Ph.D., Thomas W. Grunt, Ph.D., Barbara Peter, D.V.M., Michael Willmann, D.V.M., Harald Herrmann, M.D., Daniel Ivanov, Ph.D., Gregor Eisenwort, M.D. Ph.D., Heidrun Karlic, Ph.D., Georg Greiner, M.D. Ph.D., Karoline V. Gleixner, M.D. Ph.D., Thomas Rülicke, Ph.D., Maik Dahlhoff, D.V.M., Philipp Staber, M.D. Ph.D., Wolfgang R. Sperr, M.D., Michael Pfeilstöcker, M.D., Thomas Lion, M.D. Ph.D. MSc., Felix Keil, Gregor Hoermann

PDF-Version jetzt herunterladen Zum Volltext

Open Access 23.02.2024 | case report

Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report

Seminal vesicle metastasis from colon adenocarcinoma is very rare, with only two case reports in the literature [ 1 , 2 ]. We report a case of colon adenocarcinoma metastatic to the seminal vesicles discovered 6 years after the initial diagnosis …

verfasst von:: Juliana Arenas Hoyos, Julian Serrano Giraldo, Andres Felipe Gutierrez Rojas

PDF-Version jetzt herunterladen Zum Volltext

09.02.2024 | original report

β-adrenergic modulation of IL-6/gp130 and SOCS-1 in multiple myeloma: therapeutic strategy for stress induced-inflammatory response

Multiple Myeloma (MM) is characterized as an incurable, biologically heterogeneous disease of the plasma cells. It is defined by uncontrolled proliferation of monoclonal plasma cells in the bone marrow [ 1 ]. Bone marrow stromal cells (BMSC) are …

verfasst von:: Raika Naiebi, Saeid Abroun, Ph. D., Amir Atashi, Leila Shafiee, Mohammadarian Akbari, Mohammad Hasan Maleki, Morvarid Siri, M. Sc.

26.01.2024 | original report

Can artificial intelligence provide accurate and reliable answers to cancer patients’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline

Pain management is a significant concern for cancer patients. Even in patients undergoing curative treatment, cancer pain can be severe. Because chemotherapy-induced neuropathic pain can persist even after treatment, searching for information …

verfasst von:: Kadriye Bir Yücel, MD, Osman Sutcuoglu, MD, Ozan Yazıcı, MD, Ahmet Ozet, MD, Nuriye Ozdemir, MD

Open Access 05.12.2023 | short review

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

Implementation of targeted drugs in the treatment landscape of indolent B‑cell malignancies has facilitated long-term remissions and reduced treatment-related toxicities for a substantial proportion of patients across several disease entities.

verfasst von:: Jan-Paul Bohn, MD, PhD

PDF-Version jetzt herunterladen Zum Volltext

20.11.2023 | original report

Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study

Acute myeloid leukemia (AML) is a highly heterogeneous malignant disorder characterized by the aberrant clonal proliferation of hematopoietic stem or progenitor cells. Approximately 60–80% of adult patients with AML achieve complete remission (CR) …

verfasst von:: Yu Fu, Long Su, Yuying Li, Yehui Tan

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin